Table 2.
Trial | Year | Patients enrolled |
Experimental Design |
Duration (days) |
SAMe dose (mg/day) |
Route | Other Antidepressant |
Other dose (mg/day) |
Route | Primary Outcome Measure |
Relative Efficacy (SAMe vs. Other) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | SAMe | Other | |||||||||||
Mantero et al.53 | 1975 | 31 | 16 | 15 | double-blind | 21 | 75 | IM | Imipramine | 75 | IM | HAM-D | SAMe = Other |
| |||||||||||||
Miccoli et al.54 | 1978 | 86 | 45 | 41 | double-blind | 21 | 200 | IV | Chlorimipramine or Amitryptyline | 100 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Barberi et al.36 | 1978 | 20 | 10 | 10 | double-blind | 20 | 200 | IV | Amitriptyline | 100 | IV | HAM-D | P value for comparison not provideda |
| |||||||||||||
Del Vecchio et al.55 | 1978 | 28 | 14 | 14 | double-blind | 21 | 150 | IV | Chlorimipramine | 100 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Scarzella et al.56,b | 1978 | 20 | 10 | 10 | double-blind | 15 | 250 | IV | Chlorimipramine | 100 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Calandra et al.57 | 1979 | 24 | 12 | 12 | no blind | 15 | 150 | IV | Chlorimipramine | 100 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Monaco et al.58 | 1979 | 20 | 11 | 9 | double-blind | 15 | 200 | IV | Amitriptyline | 100 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Scaggion et al.59 | 1982 | 40 | 22 | 18 | double-dummy | 15 | 300 | IV | Nomifensine | 200 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Kufferle et al.60 | 1982 | 20 | 10 | 10 | double-blind | 18 | 150 | IV | Chlorimipramine | 50 | IV | HAM-D | SAMe = Other |
| |||||||||||||
Ubago et al.61 | 1984 | 30 | 15 | 15 | double-blind | 30 | 100 | IV | Chlorimipramine | 50 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Bell et al.62,b | 1988 | 22 | 11 | 11 | double-dummy | 14 | 400 | IV | Imipramine | 150 | PO | HAM-D | SAMe > Otherc |
| |||||||||||||
Janicak et al.43 | 1988 | 20 | 12 | 3 | double-dummy | 14 | 400 | IV | Imipramine | 150 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Cerutti et al.63 | 1989 | 20 | 20 | 20 | cross-over | 21 | 800 | PO | Minaprine | 200 | PO | HAM-D | SAMe > Otherc |
| |||||||||||||
Bell et al.64 | 1990 | 28 | 14 | 14 | double-blind | 28 | 1600 | PO | Desipramine | 250 | PO | HAM-D | SAMe = Other |
| |||||||||||||
De Vanna et al.65,b | 1992 | 30 | 15 | 15 | double-blind | 42 | 1600 | PO | Imipramine | 140 | PO | MADRS | P value for comparison not provideda |
| |||||||||||||
Bell et al.66 | 1994 | 17 | 11 | 6 | double-blind | 28 | 1600 | PO | Desipramine | 250 | PO | HAM-D | P value for comparison not provideda |
| |||||||||||||
Delle Chiale et al.50 | 1997 | 122 | 57 | 65 | double-blind | 21 | 800 | IV | Chlorimipramine | 100 | IV | HAM-D | Other > SAMed |
| |||||||||||||
Delle Chiale et al.67 | 2000 | 281 | 143 | 138 | double-blind | 42 | 1600 | PO | Imipramine | 150 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Delle Chiale et al.67 | 2000 | 295 | 147 | 148 | double-blind, dummy | 28 | 400 | IM | Imipramine | 150 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Pancheri et al.68 | 2002 | 293 | 146 | 147 | double-blind | 28 | 400 | IM | Imipramine | 150 | PO | HAM-D | SAMe = Other |
| |||||||||||||
Mischoulon et al.52 | 2014 | 189 | 64 | 65 | double-blind, cross-over | 84 | 1600-3200 | PO | Escitalopram | 10-20 | PO | HAM-D | SAMe = Other |
Both groups demonstrated significant (p<0.05) improvements on primary outcome measure. P value for between-group comparison not provided.
SAMe-treated groups only. Significant (p<0.05) improvement by Day 10.
SAMe group demonstrated significant (p<0.05) improvement compared to other antidepressant group on primary outcome measure
Other antidepressant demonstrated significiant (p<0.05) improvement compared to SAMe on primary outcome measure
Abbreviations.
HAM-D, Hamilton Rating Scale for Depression
MADRS, Montgomery-Asberg's Rating Scale for Depression